FDA Cannabis Update

After careful review, the FDA has concluded that a new regulatory pathway for CBD is needed because of the potential risk of CBD to human and animal health, and the incompatibility of CBD with food and dietary supplement regulations. The FDA is prepared to work with Congress to develop authorities for a new pathway that balances individuals’ desire for access to CBD products with the regulatory oversight to manage its risks.

Moderator

• Lezli Engelking, President & Founder, FOCUS – Foundation of Cannabis Unified Standards

Speaker

• Patrick Cournoyer, Ph.D, Senior Science Advisor, U.S. Food and Drug Administration